Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.-论文-万方医学网

第一作者： Michaël,Duruisseaux

第一单位： Centre Hospitalier Universitaire Grenoble Alpes, Thoracic Oncology Unit, Chest Department, Grenoble, France.

作者： Michaël,Duruisseaux ^[1] ; Benjamin,Besse ^[2] ; Jacques,Cadranel ^[3] ; Maurice,Pérol ^[4] ; Bertrand,Mennecier ^[5] ; Laurence,Bigay-Game ^[6] ; Renaud,Descourt ^[7] ; Eric,Dansin ^[8] ; Clarisse,Audigier-Valette ^[9] ; Lionel,Moreau ^[10] ; José,Hureaux ^[11] ; Remi,Veillon ^[12] ; Josiane,Otto ^[13] ; Anne,Madroszyk-Flandin ^[14] ; Alexis,Cortot ^[15] ; François,Guichard ^[16] ; Pascaline,Boudou-Rouquette ^[17] ; Alexandra,Langlais ^[18] ; Pascale,Missy ^[19] ; Franck,Morin ^[19] ; Denis,Moro-Sibilot ^[1]

作者单位： Centre Hospitalier Universitaire Grenoble Alpes, Thoracic Oncology Unit, Chest Department, Grenoble, France. ^[1] Medical Oncology Department, Gustave Roussy, Villejuif, France. ^[2] Assistance Publique Hôpitaux de Paris, Tenon Hospital, Chest Department, Paris, France. ^[3] Léon-Bérard Cancer Center, Lyon, France. ^[4] Centre Hospitalier Universitaire de Strasbourg, Chest Department, Strasbourg, France. ^[5] Larrey Hospital, Chest Department, Toulouse, France. ^[6] Centre Hospitalier Universitaire de Brest, Brest, France. ^[7] Oscar Lambret Cancer Center, Medical Oncology Department, Lille, France. ^[8] Centre Hospitalier Sainte Musse, Chest Department, Toulon, France. ^[9] Centre Hospitalier Général de Colmar, Louis Pasteur Hospital, Chest Department, Colmar, France. ^[10] Centre Hospitalier Universitaire d'Angers, Chest Department, Angers, France. ^[11] Centre Hospitalier Universitaire de Bordeaux, Respiratory Disease Department, Pessac, France. ^[12] Antoine Lacassagne Cancer Center, Nice, France. ^[13] Paoli Calmettes Institute, Marseille, France. ^[14] Centre Hospitalier Universitaire de Lille, Thoracic Oncology Unit, Lille, France. ^[15] Medical Oncology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France. ^[16] Assistance Publique Hôpitaux de Paris, Cochin-Port Royal Hospital, Medical Oncology Department, Paris, France. ^[17] French Cooperative Thoracic Intergroup, Department of Biostatistics, Paris, France. ^[18] French Cooperative Thoracic Intergroup, Clinical Research Unit, Paris, France. ^[19]

医学主题词腺癌(Adenocarcinoma);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);脑肿瘤(Brain Neoplasms);癌, 大细胞(Carcinoma, Large Cell);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);预后(Prognosis);蛋白激酶抑制剂(Protein Kinase Inhibitors);吡唑类(Pyrazoles);吡啶类(Pyridines);受体蛋白质酪氨酸激酶类(Receptor Protein-Tyrosine Kinases);回顾性研究(Retrospective Studies);存活率(Survival Rate);青年人(Young Adult)

DOI 10.18632/oncotarget.15746

PMID 28423535

发布时间 2022-04-09

检索历史清除

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Oncotarget

相似文献

同项目论文

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Oncotarget

相似文献

同项目论文

Oncotarget

相关期刊

检索历史清除